147 related articles for article (PubMed ID: 36308378)
1. Relapsed Childhood Acute Lymphoblastic Leukemia: Experience from a Single Tertiary Center in Thailand.
Chotsampancharoen T; Songthawee N; Chavananon S; Sripornsawan P; McNeil EB
Asian Pac J Cancer Prev; 2022 Oct; 23(10):3517-3522. PubMed ID: 36308378
[TBL] [Abstract][Full Text] [Related]
2. Relapsed Childhood Acute Myeloid Leukemia: Experience from a Single Tertiary Center in Thailand.
Songthawee N; Sripornsawan P; Chavananon S; McNeil EB; Chotsampancharoen T
Asian Pac J Cancer Prev; 2022 Dec; 23(12):4079-4084. PubMed ID: 36579988
[TBL] [Abstract][Full Text] [Related]
3. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P
Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324
[TBL] [Abstract][Full Text] [Related]
4. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
5. [Long-term outcome of childhood T-cell acute lymphoblastic leukemia treated with modified national protocol of childhood leukemia in China-acute lymphoblastic leukemia 2008].
Liao C; Shen DY; Xu XJ; Xu WQ; Zhang JY; Song H; Yang SL; Zhao FY; Shen HP; Tang YM
Zhonghua Er Ke Za Zhi; 2020 Sep; 58(9):758-763. PubMed ID: 32872717
[No Abstract] [Full Text] [Related]
6. Treatment outcomes in childhood acute lymphoblastic leukemia: 40-year experience from a single tertiary center in Thailand.
Chavananon S; Sripornsawan P; Songthawee N; McNeil EB; Chotsampancharoen T
Pediatr Hematol Oncol; 2023; 40(8):739-751. PubMed ID: 36940098
[TBL] [Abstract][Full Text] [Related]
7. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Locatelli F; Zugmaier G; Rizzari C; Morris JD; Gruhn B; Klingebiel T; Parasole R; Linderkamp C; Flotho C; Petit A; Micalizzi C; Mergen N; Mohammad A; Kormany WN; Eckert C; Möricke A; Sartor M; Hrusak O; Peters C; Saha V; Vinti L; von Stackelberg A
JAMA; 2021 Mar; 325(9):843-854. PubMed ID: 33651091
[TBL] [Abstract][Full Text] [Related]
8. Relapse of childhood acute lymphoblastic leukemia and outcomes at a reference center in Latin America: organomegaly at diagnosis is a significant clinical predictor.
Jaime-Pérez JC; Pinzón-Uresti MA; Jiménez-Castillo RA; Colunga-Pedraza JE; González-Llano Ó; Gómez-Almaguer D
Hematology; 2018 Jan; 23(1):1-9. PubMed ID: 28580844
[TBL] [Abstract][Full Text] [Related]
9. What happens to children with acute lymphoblastic leukemia in low- and middle-income countries after relapse? A single-center experience from India.
Korrapolu RSA; Boddu D; John R; Antonisamy N; Geevar T; Arunachalam AK; Joseph LL; Srinivasan HN; Mathew LG; Totadri S
Pediatr Hematol Oncol; 2023; 40(5):475-484. PubMed ID: 37477222
[TBL] [Abstract][Full Text] [Related]
10. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
Arellano ML; Langston A; Winton E; Flowers CR; Waller EK
Biol Blood Marrow Transplant; 2007 Jan; 13(1):116-23. PubMed ID: 17222760
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.
Tallen G; Ratei R; Mann G; Kaspers G; Niggli F; Karachunsky A; Ebell W; Escherich G; Schrappe M; Klingebiel T; Fengler R; Henze G; von Stackelberg A
J Clin Oncol; 2010 May; 28(14):2339-47. PubMed ID: 20385996
[TBL] [Abstract][Full Text] [Related]
12. How should childhood acute lymphoblastic leukemia relapses in low-income and middle-income countries be managed: The AHOPCA-ALL study group experience.
Espinoza D; Blanco Lopez JG; Vasquez R; Fu L; Martínez R; Rodríguez H; Navarrete M; Howard SC; Friedrich P; Valsecchi MG; Conter V; Ceppi F
Cancer; 2023 Mar; 129(5):771-779. PubMed ID: 36504077
[TBL] [Abstract][Full Text] [Related]
13. Treatment outcomes of children with acute lymphoblastic leukemia in a middle-income developing country: high mortalities, early relapses, and poor survival.
Abdelmabood S; Fouda AE; Boujettif F; Mansour A
J Pediatr (Rio J); 2020; 96(1):108-116. PubMed ID: 30240631
[TBL] [Abstract][Full Text] [Related]
14. Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433.
Lew G; Chen Y; Lu X; Rheingold SR; Whitlock JA; Devidas M; Hastings CA; Winick NJ; Carroll WL; Wood BL; Borowitz MJ; Pulsipher MA; Hunger SP
Haematologica; 2021 Jan; 106(1):46-55. PubMed ID: 32001530
[TBL] [Abstract][Full Text] [Related]
15. Excellent prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: lessons from the FRALLE 93 protocol.
Gandemer V; Chevret S; Petit A; Vermylen C; Leblanc T; Michel G; Schmitt C; Lejars O; Schneider P; Demeocq F; Bader-Meunier B; Bernaudin F; Perel Y; Auclerc MF; Cayuela JM; Leverger G; Baruchel A;
Haematologica; 2012 Nov; 97(11):1743-50. PubMed ID: 22580999
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients].
Jin FY; Zou DH; Wang GR; Xu Y; Feng SZ; Zhao YZ; Han MZ; Yan WW; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):645-8. PubMed ID: 16620547
[TBL] [Abstract][Full Text] [Related]
17. [Clinical features of children with relapsed acute lymphoblastic leukemia treated with the CCLG-ALL2008 protocol].
Chen XJ; Zou Y; Yang WY; Guo Y; Wang SC; Zhang L; Liu XM; Ruan M; Liu TF; Qi BQ; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2015 Apr; 17(4):321-6. PubMed ID: 25919548
[TBL] [Abstract][Full Text] [Related]
18. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
19. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
[TBL] [Abstract][Full Text] [Related]
20. Relapsed Acute Lymphoblastic Leukemia.
Sidhu J; Gogoi MP; Krishnan S; Saha V
Indian J Pediatr; 2024 Feb; 91(2):158-167. PubMed ID: 37341952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
